Bactiguard announces updated targets which is indicating revenues of at least SEK 600m and EBITDA of SEK 200m by 2030E. The company is stating five particular therapeutic areas of focus and will aim for at least ten application areas in either exclusivity partnerships or license partnerships 2030E. SEB looks for sales of SEK 520m and EBITDA of SEK 169m 2030E. We add further comments below.
LÄS MER